Andersen Pharma Global

Our Vision.

Strategically select, develop and register products that create and maximize value for patients and shareholders

Distinguish ourselves from the rest of the market through unique product selection, fast track developments, competitive pricing and alliance with strategic marketing partners

Our Strengths

Strategic Thinking

Highly Experienced Team

Lean Structure



High Agility / Fast Decision making

Broad Vision & Global Network

Cost consciousness / Competitiveness

Our Core Team

Our History

1

Founded




Commercialized in US:


1st Methylergonovine inj. – 2015 launched
2nd Ephedrine sulfate inj. – 2021 launched
3rd Norepinephrine inj. – 2021 launched


2

3

ANDA filed:


4th Dehydrated Alcohol – licensed-out, ANDA filed in Q2 2024
5th Carglumic acid tablet for Oral suspension 200 mg – licensed-out, ANDA filed in Q3 2024






All products Outlicensed to big US Pharmas
Healthy source of revenue flowing in to finance new projects